Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007

Janux Therapeutics, Inc.

2023-Q1 EPS reported -$0.32 revenue$1,589,000

Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.
Cash & investments $361.2M at March 31, 2022, down from $375.0M at Dec 31, 2021.
IND submitted for PSMA-TRACTr (JANX007); IND for EGFR-TRACTr (JANX008) expected 2H 2022.
Merck nominated a second target under the 2020 collaboration agreement in May 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.